Common questions about Isathal (FAQ)
Q: What are the most commonly reported side effects of Isathal?
A: According to official product information, the most commonly reported side effects of Isathal are generally localized to the eye and the site of application. These adverse reactions are classified as common and can include temporary symptoms such as a feeling of stinging, mild discomfort, irritation in the eye, and transient blurred vision.
Q: Is it normal to feel a temporary stinging or burning sensation after applying Isathal?
A: Yes, official regulatory documents classify a mild stinging or a burning sensation as a Common adverse reaction to this medicine. This feeling is typically temporary and tends to subside quickly after the eye drops are administered.
Q: How quickly should I expect to see an improvement in my symptoms after starting Isathal?
A: Regulatory documents indicate a timeframe for symptom review. Official instructions advise that if a clear clinical response is not apparent after 5 days of administration, the situation may require re-evaluation by a healthcare professional.
Q: Why do official guidelines recommend not wearing contact lenses during treatment with Isathal?
A: Official warnings state that contact lenses should not be worn while using Isathal. One reason is that the eye infection itself may cause damage. Additionally, the preservative in the drops, benzalkonium chloride, may be absorbed by and potentially discolor soft contact lenses.
Q: Is Isathal the same as other fusidic acid eye drops, like Fucithalmic?
A: Isathal and Fucithalmic both contain the active ingredient fusidic acid and are formulated as viscous eye drop suspensions. This specific pharmaceutical form is designed to provide a sustained-release effect, which helps prolong the contact time of the antibiotic on the eye surface to support its action.
Q: Can Isathal be used in both eyes if only one is infected?
A: Official administration documents note that, to help prevent cross-infection, treating both eyes is often considered, even if only one is currently infected. When this approach is taken, the guidance is often described as treating the uninfected eye first to help maintain sterility.
Q: What is the purpose of the excipients (inactive ingredients) in Isathal?
A: The excipients, or inactive ingredients, serve essential purposes in the formulation. Ingredients like Carbomer are included specifically to create the viscous, slow-release suspension. This formulation ensures the antibiotic remains on the eye's surface for an extended period, which supports its intended activity.
Q: What happens if I use Isathal for longer than the prescribed duration?
A: Official warnings included in regulatory documents emphasize that the extended or recurrent use of any antibiotic, including this medicine, carries a risk. This practice may increase the chance of bacteria developing antibiotic resistance.
Q: Is it common to see a white, crusty powder around the eye after the drops dry?
A: Yes, patient guidance often mentions that a white powder or residue may form around the eye after the eye drop suspension dries. This appearance is considered a normal, expected result of the drop's viscous formulation.
Q: Does Isathal contain a preservative like Benzalkonium chloride?
A: Yes, the product’s composition, as listed in regulatory documents, confirms that Isathal contains the excipient Benzalkonium chloride. This substance is included in the formulation specifically to act as an antimicrobial preservative.
Q: Can I use other eye drops or ointments at the same time as Isathal?
A: Authoritative patient information generally advises that a period of at least five minutes should separate the application of Isathal and any other eye drops or eye ointments. This is to ensure each medication is absorbed properly when co-administered.
Q: What should I do if I accidentally get the eye drops in my mouth?
A: Regulatory documents indicate that the amount of medication in the tube is small, making the risk of serious harm from accidental oral intake unlikely. In cases of accidental ingestion or if there is concern, it is typical to seek advice from a healthcare professional.
Q: Are there any specific eye conditions where Isathal should not be used?
A: Yes, official product information lists conditions that are known as contraindications. The medicine must not be used in cases of known hypersensitivity to any component or in infections caused by bacterial species known to be non-susceptible, such as Pseudomonas spp.
Q: What happens if a dose of Isathal is missed?
A: Official patient guidance often describes that if a dose is missed, it can be applied as soon as it is remembered. Following this, the regular dosing schedule is typically continued at the usual time. Guidance also indicates that doubling the dose to compensate for the missed one is generally not advised.
Q: Can Isathal affect the use of hormonal contraceptives?
A: Formal interaction studies for this topical eye product have not been performed. However, regulatory documents state that systemic interactions are unlikely because the amount of active ingredient absorbed into the bloodstream after application is considered negligible.
Q: How does the 'sustained release' formula of Isathal work in the eye?
A: The medicine is a viscous suspension formulated with excipients like Carbomer. When the drop is applied, it quickly liquefies upon contact with the eye, creating a depot effect. This formulation ensures prolonged retention and an extended contact time of the active ingredient with the ocular surface.
Q: Is Isathal recommended for recurrent eye infections?
A: Regulatory guidance includes a specific warning that the extended or recurrent use of the product may contribute to the risk of bacteria developing antibiotic resistance. This factor is often considered during the clinical management of recurrent infections.
